Premium
Hepatitis B and C serologic profiles of C anadian organ donors and recipients: retrospective 10‐year review at a single center
Author(s) -
Burton C.E.,
Doucette K.E.,
Mabilangan C.A.,
Plitt S.S.,
Lee B.E.,
Preiksaitis J.K.
Publication year - 2016
Publication title -
transplant infectious disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.69
H-Index - 67
eISSN - 1399-3062
pISSN - 1398-2273
DOI - 10.1111/tid.12558
Subject(s) - medicine , serology , hepatitis c , retrospective cohort study , hepatitis b , virology , center (category theory) , immunology , antibody , chemistry , crystallography
Abstract Background Hepatitis C virus ( HBV ) and hepatitis C virus ( HCV ) are important causes of hepatitis and can be transmitted from organ donor to recipient. This study aimed to determine HBV and HCV serologic profiles of a population of Canadian solid organ transplant ( SOT ) donors and recipients, including prevalence of recipient HBV immunity. Methods Data on age, gender, organ transplanted, and pre‐transplant HBV and HCV serology for SOT donors and recipients at a Canadian hospital from 2001 to 2011 were obtained from a transplant database. Results There were 2455 recipients (2205 adults, 250 children), and 1559 donors. Over 50% of adult and 44% of pediatric recipients were HBV non‐immune pre‐transplant. Pediatric recipients were more likely to have HBV vaccine immunity than were adult recipients (48.8% vs. 28.9%, P < 0.001). Prevalence of HBV vaccine immunity was highest in renal recipients (48.3% in adult, 63.2% in pediatric recipients). Recipient HBV vaccine immunity increased from 5.8% in 2001 to 44.5% in 2011 ( P < 0.001). Of 134 adult recipients with prior HBV infection, 59 (44%) were co‐infected with HCV . Only 0.6% of adult non‐liver recipients had acute or chronic HBV infection and 3.2% were anti‐ HCV positive. Only 2 donors had acute or chronic HBV infection, 29 had prior HBV infection, 9 were isolated hepatitis B core antibody positive, and 15 were anti‐ HCV positive. Conclusions The prevalence of HBV vaccine immunity in SOT candidates is low, but increased from 2001 to 2011. Opportunities for quality improvement in pre‐transplant HBV immunization exist. HCV co‐infection is common in recipients with prior HBV infection. Prevalence of HCV infection in non‐liver transplant recipients is low.